Completed PHASE1 INTERVENTIONAL 4-arm NCT02765724

Determine Pacritinib Pharmacokinetics in Impaired Hepatic Patients and Healthy Subjects

A Phase 1 Open Label, Single Dose, Parallel-Group Study to Determine the Pharmacokinetics of Pacritinib in Patients With Impaired Hepatic Function in Comparison With Healthy Subjects

Sponsor: CTI BioPharma

Conditions Myelofibrosis

Interventions Pacritinib

Updated 8 times since 2017 Last updated: Mar 4, 2020 Started: Jan 31, 2015 Primary completion: Jun 30, 2015 Completion: Jun 30, 2015

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1 trial investigates Myelofibrosis and is currently completed. CTI BioPharma leads this study, which shows 8 recorded versions since 2015 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

8 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE1
Sep 2024 — Sep 2025 [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Apr 2020 — Jan 2021 [monthly]

Completed PHASE1

▶ Show 3 earlier versions

Jun 2018 — Apr 2020 [monthly]

Completed PHASE1
Feb 2017 — Jun 2018 [monthly]

Completed PHASE1
Jan 2017 — Feb 2017 [monthly]

Completed PHASE1

First recorded

Jan 2015

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

CTI BioPharma
SGS S.A.

Data source: CTI BioPharma

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Chisinau, Moldova
• Munich, Germany